AstraZeneca PLC

ZEG

Company Profile

  • Business description

    A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.

  • Contact

    1 Francis Crick Avenue
    Cambridge Biomedical Campus
    CambridgeCB2 0AA
    GBR

    T: +44 2037495000

    E: ir@astrazeneca.com

    https://www.astrazeneca.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    94,300

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,637.8012.900.15%
CAC 407,779.728.38-0.11%
DAX 4023,968.3069.89-0.29%
Dow JONES (US)42,015.0783.63-0.20%
FTSE 1008,716.459.56-0.11%
HKSE23,573.38315.071.35%
NASDAQ19,194.9193.970.49%
Nikkei 22538,432.98710.581.88%
NZX 50 Index12,281.3180.95-0.65%
S&P 5005,900.1311.580.20%
S&P/ASX 2008,409.8012.900.15%
SSE Composite Index3,363.4523.510.70%

Market Movers